{"ticker": {"uuid": "231006cc-9a48-40d6-9ca0-a344e86c847d", "symbol": "UNCY", "name": "Unicycive Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group", "summary": "Maxim Group analyst Jason McCarthy reiterated a Buy rating for Unicycive Therapeutics (UNCY) with a $30.00 price target, despite the company's recent quarterly GAAP net loss of $12.82 million. The Street maintains a Strong Buy consensus with an average price target of $36.71. Ben", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3289523/unicycive-therapeutics-uncy-gets-a-buy-from-maxim-group/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T08:42:33", "published_display": "15 Jul 2026 08:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval", "summary": "Shares of Unicycive Therapeutics Inc (UNCY) jumped 9% as retail investors speculated on the potential FDA approval of its drug, Oxylanthanum carbonate (OLC). The company resubmitted its application for OLC, a treatment for hyperphosphatemia in chronic kidney disease patients on d", "url": "https://stocktwits.com/news-articles/markets/equity/uncy-retail-buzz-explodes-this-week-as-traders-bet-big-on-experimental-drug-approval/cZ7HuN1RIFf", "source_name": "Stocktwits", "published_at": "2026-07-14T14:42:33", "published_display": "14 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY: Unicycive Therapeutics Investors with Losses Should", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxORHgxeW13UGxiY2JSanBCM016aW1xTWtBMlBQR2h6OGxoWHNHN25PZU83UDhSNXVSeUEyVG5ZVHg0R013RUk3RjBVaWJzYWdEMUlhNzU4QjdTMk5kTVliQVJjNlBlbVo5blUyR0E3WE1POVFzWWk1SVJXT01rN3gzR0cxRzRoWjhMbjE5OU5tQ0dKUGEwa0VQeXFTZnJJY3hUNW5hamdRX3NPQm5jdVBvT19aQ210blk4aXluYXNIZGVFek5SRHhwUFg5UTNMMnZhdHlwRHBoS3VSYllrbFV4VC1ZRGRxQXFfbHBRVk9pWjRkUVEtRm92S29YbkVTbTVUanUxWmZ4ek8zdllTaW93SGdOTUZoUQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-07-13T18:05:18+00:00", "published_display": "13 Jul 2026 18:05", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation", "summary": "Block & Leviton is investigating Unicycive Therapeutics, Inc. (UNCY) for potential securities law violations after the FDA issued a second Complete Response Letter for its OLC New Drug Application due to third-party manufacturing deficiencies. Investors who have lost money in Uni", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326412/23044/en/uncy-unicycive-therapeutics-investors-with-losses-should-contact-block-leviton-about-securities-fraud-investigation.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T17:39:34", "published_display": "13 Jul 2026 17:39", "sentiment": "negative", "sentiment_pct": 25, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.", "summary": "Kirby McInerney LLP is investigating Unicycive Therapeutics, Inc. regarding potential violations of federal securities laws after the FDA issued a second Complete Response Letter for the company's kidney disease therapy, causing a significant stock price drop. Investors who purch", "url": "https://www.globenewswire.com/news-release/2026/07/11/3325784/0/en/uncy-investor-alert-kirby-mcinerney-llp-investigates-potential-claims-involving-unicycive-therapeutics-inc.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T23:41:27", "published_display": "10 Jul 2026 23:41", "sentiment": "negative", "sentiment_pct": 26, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (Nasdaq:UNCY) - Stock Analysis", "summary": "Unicycive Therapeutics (Nasdaq:UNCY) is a clinical-stage biotechnology company focused on kidney disease therapies. The company has recently faced setbacks with its oxylanthanum carbonate drug application due to manufacturing deficiencies, leading to significant stock price drops", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uncy/unicycive-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-07-09T22:41:27", "published_display": "09 Jul 2026 22:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium-affiliated holders disclose 271,456 shares in Unicycive Therapeutics (UNCY)", "summary": "A Schedule 13G/A filing reveals that Millennium-affiliated entities, including Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, beneficially own 271,456 shares (1.0%) of Unicycive Therapeutics (UNCY). Separately, Integrated Core Strategies (US)", "url": "https://www.stocktitan.net/sec-filings/UNCY/schedule-13g-a-unicycive-therapeutics-inc-amended-passive-investment--9938be64ee22.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:11:09", "published_display": "08 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced \u2013 Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz", "summary": "The Law Offices of Frank R. Cruz announced an investigation into Unicycive Therapeutics, Inc. (UNCY) for possible federal securities law violations. This follows a significant stock price drop after Unicycive disclosed a second Complete Response Letter from the FDA for its kidney", "url": "https://aijourn.com/securities-fraud-investigation-into-unicycive-therapeutics-inc-uncy-announced-shareholders-who-lost-money-urged-to-contact-the-law-offices-of-frank-r-cruz/", "source_name": "The AI Journal", "published_at": "2026-07-07T22:44:54", "published_display": "07 Jul 2026 22:44", "sentiment": "negative", "sentiment_pct": 26, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Unicycive Therapeutics, Inc. \u2013 NASDAQ:UNCY", "summary": "The article focuses on the \"Price to book forward\" metric for Unicycive Therapeutics, Inc. (NASDAQ: UNCY). It appears to be a financial data snippet from TradingView, indicating a specific financial ratio without providing extensive details or analysis. The content primarily list", "url": "https://www.tradingview.com/symbols/NASDAQ-UNCY/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T08:41:37", "published_display": "05 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Unicycive Therapeutics, Inc. \u2013 NASDAQ:UNCY", "summary": "The article discusses the forward price-to-earnings ratio for Unicycive Therapeutics, Inc. (NASDAQ: UNCY). It provides financial data and links to various tools and resources available on the TradingView platform for analyzing the stock.", "url": "https://www.tradingview.com/symbols/NASDAQ-UNCY/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T04:40:18", "published_display": "05 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY - Unicycive Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Unicycive Therapeutics Inc (UNCY) from Finviz. It includes a comprehensive overview of the company's financial data, stock performance metrics, insider ownership, institutional ownership, and analyst ratings. Key financi", "url": "https://finviz.com/stock?t=UNCY&b=2&p=d&ty=lf", "source_name": "Finviz", "published_at": "2026-07-04T21:41:34", "published_display": "04 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY - Unicycive Therapeutics Inc Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for Unicycive Therapeutics Inc (UNCY). It includes key financial metrics such as market capitalization, income, sales, EPS, and various ratios, alongside performance indicators like 52-week high/low, volatility, and", "url": "https://finviz.com/stock?t=UNCY&ta=1&p=d&ty=fc&b=2", "source_name": "Finviz", "published_at": "2026-07-04T20:41:38", "published_display": "04 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Unicycive Therapeutics (UNCY) Is Down 19.6% After FDA CRL Over Third-Party Manufacturing Issues And What's Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-04T17:34:01+00:00", "published_display": "04 Jul 2026 17:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY - Unicycive Therapeutics Inc Short Interest", "summary": "This article provides a detailed financial overview of Unicycive Therapeutics Inc (UNCY), focusing on its short interest. It covers key financial metrics, stock performance data, insider and institutional ownership, and various ratios, painting a comprehensive picture of the comp", "url": "https://finviz.com/stock?t=UNCY&b=2&p=d&ty=si", "source_name": "Finviz", "published_at": "2026-07-04T03:39:08", "published_display": "04 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the Firm", "summary": "Bragar Eagel & Squire, P.C. is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of its stockholders after the company announced a second Complete Response Letter from the FDA for its New Drug Application. This news led to a nearly 39% decline in Unicycive's sha", "url": "https://www.mycarrollcountynews.com/online_features/press_releases/article_15e47430-1e3d-5a52-bdd1-4616ad0a271d.html", "source_name": "Carroll County Mirror-Democrat", "published_at": "2026-07-02T17:40:45", "published_display": "02 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics reports $61.4M cash balance as of June 30, 2026", "summary": "Unicycive Therapeutics reported a preliminary cash balance of approximately $61.4 million as of June 30, 2026, indicating available liquidity. These stated results are preliminary, prepared by management, and have not been audited or reviewed by independent accountants. The compa", "url": "https://www.tradingview.com/news/tradingview:604c25e81556d:0-unicycive-therapeutics-reports-61-4m-cash-balance-as-of-june-30-2026/", "source_name": "TradingView", "published_at": "2026-07-02T14:40:44", "published_display": "02 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (UNCY) discloses $61.4M cash balance in preliminary Q2 2026 update", "summary": "Unicycive Therapeutics, Inc. reported a preliminary, unaudited cash balance of approximately $61.4 million as of June 30, 2026, as part of its second-quarter results. The company disclosed this information via an 8-K filing under Item 8.01, indicating a material event deemed impo", "url": "https://www.stocktitan.net/sec-filings/UNCY/8-k-unicycive-therapeutics-inc-reports-material-event-6447090bf357.html", "source_name": "Stock Titan", "published_at": "2026-07-02T14:40:44", "published_display": "02 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies", "summary": "Unicycive Therapeutics (UNCY) shares dropped 33.1% after the FDA issued a Complete Response Letter for its oxylanthanum carbonate NDA, citing third-party manufacturing deficiencies. The letter raised no concerns about clinical efficacy or safety, but instead highlighted unresolve", "url": "https://finance.yahoo.com/healthcare/articles/unicycive-therapeutics-uncy-down-33-221333290.html", "source_name": "Market source", "published_at": "2026-07-02T04:13:00", "published_display": "02 Jul 2026 04:13", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud", "summary": "Kirby McInerney LLP is investigating potential securities fraud claims against Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This investigation follows a significant 39% stock price drop after Unicycive announced a second Complete Response Letter from the FDA regarding its kidney ", "url": "https://www.businesswire.com/news/home/20260701488460/en/UNICYCIVE-THERAPEUTICS-INC.-INVESTOR-ALERT-Kirby-McInerney-LLP-Announces-Investigation-Into-Potential-Securities-Fraud", "source_name": "Business Wire", "published_at": "2026-07-01T22:39:18", "published_display": "01 Jul 2026 22:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Unicycive Therapeutics, Inc. SEC Filing", "summary": "This article reports on Unicycive Therapeutics, Inc.'s SEC Form 144 filing, which indicates a proposed sale of securities. The filing details the filer information, issuer information, securities to be sold including details of acquisition and payment, and confirms no securities ", "url": "https://www.stocktitan.net/sec-filings/UNCY/144-unicycive-therapeutics-inc-sec-filing-2a394680be50.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:39:18", "published_display": "01 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY ALERT: Unicycive Therapeutics, Inc. Investigated for", "summary": "Block & Leviton is investigating Unicycive Therapeutics, Inc. (UNCY) for potential securities law violations after the FDA issued a second Complete Response Letter for its OLC New Drug Application, citing unresolved third-party manufacturing deficiencies. This news led to a decli", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320812/23044/en/uncy-alert-unicycive-therapeutics-inc-investigated-for-securities-fraud-by-block-leviton-investors-who-lost-money-encouraged-to-contact-the-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T15:10:05", "published_display": "01 Jul 2026 15:10", "sentiment": "negative", "sentiment_pct": 25, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Unicycive Therapeutics Stock Falling Tuesday?", "summary": "Unicycive Therapeutics' stock fell over 46% after the FDA issued a Complete Response Letter (CRL) for its kidney disease drug application, citing third-party manufacturing deficiencies. This is the second time the FDA has raised these concerns, despite the company's belief that t", "url": "https://www.sahmcapital.com/news/content/why-is-unicycive-therapeutics-stock-falling-tuesday-2026-06-30", "source_name": "Sahm", "published_at": "2026-07-01T13:39:18", "published_display": "01 Jul 2026 13:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Inc", "summary": "Unicycive Therapeutics announced that the U.S. FDA has declined to approve its kidney disease drug for elevated phosphate levels in chronic kidney disease patients on dialysis. The FDA cited deficiencies at a third-party manufacturing facility as the reason for the non-approval.", "url": "https://www.reuters.com/company/unicycive-therapeutics-inc/", "source_name": "Reuters", "published_at": "2026-07-01T08:40:18", "published_display": "01 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Receives FDA Complete Response Letter for Oxylanthanum Carbonate NDA", "summary": "Unicycive Therapeutics announced it received a Complete Response Letter (CRL) from the FDA for its oxylanthanum carbonate (OLC) NDA, citing deficiencies at a third-party manufacturing vendor, not related to clinical efficacy or safety. The company is actively discussing labeling ", "url": "https://www.einpresswire.com/article/923415095/unicycive-therapeutics-receives-fda-complete-response-letter-for-oxylanthanum-carbonate-nda", "source_name": "EIN Presswire", "published_at": "2026-07-01T04:17:00", "published_display": "01 Jul 2026 04:17", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY Stock Clocks Worst Day In A Year \u2014 Analysts Keep Buy Ratings Despite \u20185-12 Month Delay\u2019 In Drug Approval", "summary": "Unicycive Therapeutics (UNCY) experienced its worst day in over a year after the FDA again refused to approve its drug oxylanthanum carbonate due to third-party manufacturing issues. Despite the setback and potential 5-12 month delay, B. Riley and H.C. Wainwright maintained their", "url": "https://stocktwits.com/news-articles/markets/equity/uncy-stock-clocks-worst-day-in-year-analysts-keep-buy-ratings-despite-5-12-month-delay-in-drug-approval/cZ1QMSoR70o", "source_name": "Stocktwits", "published_at": "2026-06-30T17:34:00", "published_display": "30 Jun 2026 17:34", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors", "summary": "Johnson Fistel, PLLP is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) following a decline in its stock price. This investigation comes after the FDA issued a second Complete Response Letter for Unicycive's OLC NDA due to unresolved third-party manufacturing deficienci", "url": "https://www.globenewswire.com/news-release/2026/06/30/3320031/0/en/johnson-fistel-investigates-unicycive-therapeutics-inc-nasdaq-uncy-on-behalf-of-investors.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T16:41:38", "published_display": "30 Jun 2026 16:41", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive gets FDA CRL for OLC kidney drug application", "summary": "Unicycive Therapeutics (NASDAQ:UNCY) received a Complete Response Letter (CRL) from the FDA for its oxylanthanum carbonate New Drug Application. The CRL cited third-party manufacturing deficiencies as the reason, with no issues raised regarding the drug's safety or efficacy. The ", "url": "https://grafa.com/en/news/united-states/unicycive-therapeutics-fda-crl-oxylanthanum-carbonate", "source_name": "grafa.com", "published_at": "2026-06-30T14:41:38", "published_display": "30 Jun 2026 14:41", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY Extends ATM Offering As Dilution Fears Hit The Chart", "summary": "Unicycive Therapeutics Inc. (NASDAQ: UNCY) shares have fallen by 46.04% due to investor concerns over clinical and financing uncertainties. The company filed a $150 million mixed securities shelf and expanded its at-the-market (ATM) equity program with Guggenheim Securities from ", "url": "https://stockstotrade.com/news/unicycive-therapeutics-inc-uncy-news-2026_06_30/", "source_name": "StocksToTrade", "published_at": "2026-06-30T13:41:38", "published_display": "30 Jun 2026 13:41", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA rejects drug again for same manufacturing issue, chopping stock in half", "summary": "The FDA has rejected Unicycive's kidney disease drug a second time, specifically citing an ongoing manufacturing issue with its Indian supplier. This decision caused the company's stock to drop by half. Despite the manufacturer supplying drugs for other U.S. companies, the FDA ha", "url": "https://www.bizjournals.com/sanfrancisco/news/2026/06/30/fda-unicycive-pdufa-dialysis-hyperphosphatemia.html", "source_name": "The Business Journals", "published_at": "2026-06-30T13:41:38", "published_display": "30 Jun 2026 13:41", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Gets FDA's Complete Response Letter for Resubmitted Oxylanthanum Carbonate NDA", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/unicycive-therapeutics-gets-fda-apos-122541738.html", "source_name": "MT Newswires", "published_at": "2026-06-30T12:25:41+00:00", "published_display": "30 Jun 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/unicycive-therapeutics-receives-complete-response-110500532.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T11:05:00+00:00", "published_display": "30 Jun 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Unicycive's kidney disease drug", "summary": "The U.S. FDA has declined to approve Unicycive Therapeutics' drug oxylanthanum carbonate (OLC) for chronic kidney disease patients due to deficiencies at a third-party manufacturing facility. This marks a second setback for the company, although the FDA had no concerns about the ", "url": "https://www.reuters.com/legal/litigation/us-fda-declines-approve-unicycives-drug-dialysis-patients-2026-06-30/", "source_name": "Reuters", "published_at": "2026-06-30T11:12:00", "published_display": "30 Jun 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNSEtlRDA2bmZmUnJubXJUMEJkeDJUUDlzWGg3ZEdjTmVva0hMcW5LcGhZSHZieF9wdTIwcHR5N1NheTFKYnpiZ2NTOFQ4SmNlZ2tfaVpWY1J6ZEVmODRNck56amRUSmFnZGhwLXgyZTRXWU1jQklvVnU0TlBieEJfcXF1Zmw1VW54V2ZfU2I4WTV0VHgwRlR2RHJwRQ?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Unicycive Therapeutics Stock Falling Tuesday? - Unicycive Therapeutics (NASDAQ:UNCY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPXzdRX1RURTVEbUh0V1RNa1Ayajk1TFcwbmo5bmlmQ2E0M1JjOXRNYXlLajRsRkR3UjFWZW1DRXJTVDJDdUdpU2g2d0wtWEs2V1FLVG02QXk2T1RPWTdJaDM0ZGlGQlBPT2JrYzdRMWpyNnZhMmZneVppVFhEM2RGTFB6WEtZRjFuakU5YTV1bFR1Wkw2Y2FmM3IyRVdKWUVKTVE?oc=5", "source_name": "Benzinga", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive\u2019s kidney drug hits FDA setback as label talks continue", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNSXVHd1RnSVJ4aTA0WEFPdkFXRDRKMHZBbGxJd0cwVDBPY3FiSDRxZjFWV2hYeUJfZDRhSkdWbjdiUVppeEZzcGxIcVVlSndBZllqRHEtRUo0eWRWZVM0SklqckRhc29DSWsxV0dyRlJGMFNvLWdpOENISnAwMk1DTEx0WDJGVW1WV3c4bW9rRW81alNfZHFwRFlYbzdLS2luUFkxV1NmaUNHVUo3RjRaYTBmZGVfNTRvMTk3TA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics stock tumbles on FDA rejection letter", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPRVMzZVI3allQaHR2T2hTRGhNc2ZqV1hsU3RBWGlDSVhEMnJmTE84QzZvWGNVZG9tbERVRFFMRUU4ZV9oQmN3Nm9lQWw2Uk1hTVljMWRuZnhNTHJEMFN3S1RYUnMwQjMxTjQ1QnZQckJpaXczNi1XLXZTMXp3UUtzU1lnNWRsWldVancyWE1FT2JWTl9RR3RjSzVjZ3doRDZnVUx4cWk2LXk4bE1HTXI5N2V4dVdNdlJVN1FTMGdfZw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive (UNCY) investors back board slate and 2026 auditor at meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQeGpheDBmNUQzNzF1amU5MWdpUllPN3RfaUlBX1BOUFlmUkZsVUI4LVdQREY1RlVjYzQ3UmZ6eHNTdDVCMjVKcjdod1RVX2pXdU8yUzZRcTl2QXdNNE5RbWQ3dHpFbGJfRnAyeDBOdThBQlNaeFl1U0M1UnNITDAtbW9mTVFRWWprZU9MdEc2RGh1N2paZlhPUFMxQTJzNHpjTHQ0VEdJTnNoRzdfSl93REVRVVZ4QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Stock - Wednesday strategy and pipeline snapshot", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxORjIyd3JqMWdjaHJydzFwVXhmcWFFVm1qd1JPY19LLXk0eHZldXB6QjI0cEhWX0pzX0wycV9kcUJKTjJ0clh1R1drcUJSWElxS2kzLVkySGtuVEtnVTJVemlrMktmUlRiM0xDN1RuT2hpVWFxV2VVU1dqZ2dEWUZXb2pvLWFrNHl1WHBKYUhLbnYyTGhPVUd0anBoanpEYVF5TUNaM25NQ09nUl9lQVFNNUQ5aGx6SFhILU5EWjNMdUMtRktoZWIw?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Unicycive Therapeutics, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPaXZydUh6eDlad0NlMVJpZEJ2SW5aXzh3cXFMbmUxVVRyUXBZRXB0UlllVTZlM09DNDJnM3E0c0NvTXdxZUZwT3ZKR0h5Q3FFWHlQZ2JJQW1HbGlOSDZTX2F2eHVzcTg3cmZuT2F5djVDSVRxeWVkcmExM1dkNVpnYUw1ZHNTaFBuLVRiTFRsSVNUa2UwUFg2WWN0dXM3Q1VHLU53OVd4QkZBQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (UNCY) CFO awarded 169,500 RSUs as stock compensation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQMHFkWFA2ZjE0T1E5RjhheDcwSWxydlJjSWRkSk95WndqVFk2UnJ0YUU4T3BrTDlNQzdjNHhVTVNBVlUxMGZuZWJwN2lDWVcxSVNhVi1vaEtKY3FmZl9KSUVYZ2toMkhGZjFqOHdzejY5b2RQSmhyUmlPVHFnZzhJSGFRTWJzcW1SUjl1cjJrbWc1Y3I0Y2ZmR19SM2pVQjZ3THFqUGx3WnFraG1ra3daM01sTWFQUF9lbExGT0MwWnNqTENCXzJYM0Zn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (UNCY) director receives sizeable new RSU awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQMGJKWkIxbWxmMGdWNk9lNGZNNF9aelZJemI4VjZwbnYyRXNkT0RwVEVsZFhYRG5wN2VaRHFYTExILVRmd3dpV1dISnFVaDlzY3ZtOHBCSU5QTVNqTXRtZkVIM05KY2RaMjVXM3Rpa3JmeXd0cmx1UW5fWjdycV9LUE1SaWhNUGhJUzhnNkc2Nmc1bXVfYlBweFItN2QtOHl5SzZabEdoWkVicGQ2bEo3STB6ZEpvRW96ck1LdXhCRHNfbWNrRFF4TkxR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyperphosphatemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 \u2013 DelveInsight | Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwJBVV95cUxQY1pPdElwWmZfMTEwUkpJUVhHRlhGWGxLMEVLaFZnUUE1SmlPNjJDNjdxWGcydEtoeEdrV09mYnBzMTg3R28wbU9YcmF3YlhXVFhHWXBhMU0zeTRCWGxGSWJUTndlZWJKb1JTcTJJZXJmVVFXaWkwVDktVHhzb2VMWE9WbDlrVHFZa1JOQWUxaVZlb044el95OGZ0eTZtTXpVaG5zZm5jdzZJZzhMZDBGMlFOS1VmSzRhRUk4SlNkLTU2dUVjWl9PaEVvVS1CNWpWUU01TzdkQm5HM3VoTU5YRUFIcG9YY0xSV3NmUVA5RS1zQ25HcGNyMkg3NmR3TFEwNXpNTnpMRGdhQUNCT1RxN2hUTTdMS3BLQWprNHVKeEdxM0lLdTF5a2xmMC1semdCU0pWaXl0aG4xaGpPbTY4WTMwbVd1Z3AxTXVGTkNFOA?oc=5", "source_name": "Barchart.com", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Raises ATM Offering of Shares", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/unicycive-therapeutics-raises-atm-offering-205833576.html", "source_name": "MT Newswires", "published_at": "2026-06-05T20:58:33+00:00", "published_display": "05 Jun 2026 20:58", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbjJHQS1tQVhGWkRqcGFOaW1VaTdXNFlvSV9hVlFfZXExVks0VkxmOTNmd1RONFhUR3o2VFplQnN6ZHBrZWdWM1lJSE1HaXZ5NGZySmVyNUEydmJGcGpzUFp4aFZCblhQdVJsWnJ5WXNpdFU5UmxISUpXQW9hV2w2cHdzbWUxZFNoMjlqdXF0ZE1wTW5vMFl1eThpNndfRU5jWDZ3VVVlWkNqd1Y1amtKQ1dDbC1pYU1I?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (UNCY) CEO receives 762,200 restricted stock units award", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNODhEQmd3dzl0dmk2MHd1cjRWRHF2aTMwY051aGNRUlpiYlk5ZU9zU3l0NDlwSmRMTG9Ba2N0WXJ0QUdNS2o4M1VCRHJZc19pMkdfeEZUUnlZTDdId3FIUW9uRU1UNENMeWNjU0ZKUVUyRDZuVVc0cHl3cXlxZEZ1cjAwWFJlelFacHB3NXpVU3daRnFvMGNEeWFWdXZ3VWt6S3BaUXpkNUtia3NzUW1CQ2hNQnc3S0htZlJ2dg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQN2dnLUNwTjc0T09WcElCQjBZb3U0UmdyRTd4dklsQU5FMVNJQUZVX09xOXV5MGVNMENPNWxXTE5EbU43TmpwUlJ5dW1Rd0hHV0hKT1A5OVVIaFM3ZXJvcU5tSG8tT1JNU0l3LUd4NTlrY0tmc2FiajNzWWNXYUVndW85RVBSX1hHemhGVUpCM3ZpQldkWkZkLWRITEpqYWtyeUIxZ0N1R2dEdw?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unicycive Therapeutics Releases Q1 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQWVlkVjV3bUdGSWFsN0NVbDYzeVhJekdoZzdQMENMR3phX0NxbEtXa3FrQlpwU0trbmpPUFM4Y1UyQmUzQjR2ZTZOcC0wcUdoTEZqVlQtWGxKa1VZMHZtUjludzlEVjVJaHhSeTF6Zkc0UTBZbUNnZ1lqeFJjYlNtSWhnUlotOHFZbWlWeFhfaXrSAZABQVVfeXFMUFlZZFY1d21HRklhbDdDVWw2M3lYSXpHaGc3UDBDTEd6YV9DcWxLV2txa0JacFNLa25qT1BTOGNVMkJlM0I0dmU2TnAtMHFHaExGalZULVhsSmtVWTB2bVI5bnc5RFY1SWh4UnkxemZHNFEwWW1DZ2dZanhSY2JTbUloZ1JaLThxWW1pVnhYX2l6?oc=5", "source_name": "AlphaStreet", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unicycive CEO gets April 15 speaking slot at Needham healthcare event", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZGJvSUNTM3RwZGd2cFVBZVpEUEM4aFF6NHloeTE3M0F4VmtqS2xaM3MxV3k4dzAzaU9xaW00RG5aRzVQTkZPRDVEM1Q0dkEwMTlWRHpBcmJRNmFjSkRZU1kxVW9IU2t5eUNfMk9oMkM0cHJMNFZqWUFuNU9qRFZMQjBUTHhhVDdmYkZqaUZmOGszSkptdnlTMFdlQTdOeS03QVRaUDhabk14VjY3Qk9iVm5XbmdrZlNJT0xoRlVBVzc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Unicycive Therapeutics (NASDAQ:UNCY) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive readies kidney drug launch with FDA decision due June 29", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNSmIyR01ucGJObTZ3MkVSbk52SzZKLTZKYmE3XzJjbVJqSlNUUTNJU01IRTVkakVLMmRETy1ocXkwZnFLS3FmVjJUTDk0OHBMR21Nb3MzeGd3OFBfel8zbTdDRWVkYmdtRUM0QTBlX2dPUnZCeTU0QktzQlBjY29JcnNTRnk3aFRpYTB6czRqN19ob2ZqWHdBUmtkYjd3dmNyNU8wVVByVGFCaWMxaV9QUUZadlI1c0F5cjJpWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We Might See A Profit From Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Soon", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group", "summary": "Maxim Group analyst Jason McCarthy reiterated a Buy rating for Unicycive Therapeutics (UNCY) with a $30.00 price target, despite the company's recent quarterly GAAP net loss of $12.82 million. The Street maintains a Strong Buy consensus with an average price target of $36.71. Ben", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3289523/unicycive-therapeutics-uncy-gets-a-buy-from-maxim-group/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T08:42:33", "published_display": "15 Jul 2026 08:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval", "summary": "Shares of Unicycive Therapeutics Inc (UNCY) jumped 9% as retail investors speculated on the potential FDA approval of its drug, Oxylanthanum carbonate (OLC). The company resubmitted its application for OLC, a treatment for hyperphosphatemia in chronic kidney disease patients on d", "url": "https://stocktwits.com/news-articles/markets/equity/uncy-retail-buzz-explodes-this-week-as-traders-bet-big-on-experimental-drug-approval/cZ7HuN1RIFf", "source_name": "Stocktwits", "published_at": "2026-07-14T14:42:33", "published_display": "14 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY: Unicycive Therapeutics Investors with Losses Should", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxORHgxeW13UGxiY2JSanBCM016aW1xTWtBMlBQR2h6OGxoWHNHN25PZU83UDhSNXVSeUEyVG5ZVHg0R013RUk3RjBVaWJzYWdEMUlhNzU4QjdTMk5kTVliQVJjNlBlbVo5blUyR0E3WE1POVFzWWk1SVJXT01rN3gzR0cxRzRoWjhMbjE5OU5tQ0dKUGEwa0VQeXFTZnJJY3hUNW5hamdRX3NPQm5jdVBvT19aQ210blk4aXluYXNIZGVFek5SRHhwUFg5UTNMMnZhdHlwRHBoS3VSYllrbFV4VC1ZRGRxQXFfbHBRVk9pWjRkUVEtRm92S29YbkVTbTVUanUxWmZ4ek8zdllTaW93SGdOTUZoUQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-07-13T18:05:18+00:00", "published_display": "13 Jul 2026 18:05", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation", "summary": "Block & Leviton is investigating Unicycive Therapeutics, Inc. (UNCY) for potential securities law violations after the FDA issued a second Complete Response Letter for its OLC New Drug Application due to third-party manufacturing deficiencies. Investors who have lost money in Uni", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326412/23044/en/uncy-unicycive-therapeutics-investors-with-losses-should-contact-block-leviton-about-securities-fraud-investigation.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T17:39:34", "published_display": "13 Jul 2026 17:39", "sentiment": "negative", "sentiment_pct": 25, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.", "summary": "Kirby McInerney LLP is investigating Unicycive Therapeutics, Inc. regarding potential violations of federal securities laws after the FDA issued a second Complete Response Letter for the company's kidney disease therapy, causing a significant stock price drop. Investors who purch", "url": "https://www.globenewswire.com/news-release/2026/07/11/3325784/0/en/uncy-investor-alert-kirby-mcinerney-llp-investigates-potential-claims-involving-unicycive-therapeutics-inc.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T23:41:27", "published_display": "10 Jul 2026 23:41", "sentiment": "negative", "sentiment_pct": 26, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (Nasdaq:UNCY) - Stock Analysis", "summary": "Unicycive Therapeutics (Nasdaq:UNCY) is a clinical-stage biotechnology company focused on kidney disease therapies. The company has recently faced setbacks with its oxylanthanum carbonate drug application due to manufacturing deficiencies, leading to significant stock price drops", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uncy/unicycive-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-07-09T22:41:27", "published_display": "09 Jul 2026 22:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium-affiliated holders disclose 271,456 shares in Unicycive Therapeutics (UNCY)", "summary": "A Schedule 13G/A filing reveals that Millennium-affiliated entities, including Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, beneficially own 271,456 shares (1.0%) of Unicycive Therapeutics (UNCY). Separately, Integrated Core Strategies (US)", "url": "https://www.stocktitan.net/sec-filings/UNCY/schedule-13g-a-unicycive-therapeutics-inc-amended-passive-investment--9938be64ee22.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:11:09", "published_display": "08 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced \u2013 Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz", "summary": "The Law Offices of Frank R. Cruz announced an investigation into Unicycive Therapeutics, Inc. (UNCY) for possible federal securities law violations. This follows a significant stock price drop after Unicycive disclosed a second Complete Response Letter from the FDA for its kidney", "url": "https://aijourn.com/securities-fraud-investigation-into-unicycive-therapeutics-inc-uncy-announced-shareholders-who-lost-money-urged-to-contact-the-law-offices-of-frank-r-cruz/", "source_name": "The AI Journal", "published_at": "2026-07-07T22:44:54", "published_display": "07 Jul 2026 22:44", "sentiment": "negative", "sentiment_pct": 26, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Unicycive Therapeutics, Inc. \u2013 NASDAQ:UNCY", "summary": "The article focuses on the \"Price to book forward\" metric for Unicycive Therapeutics, Inc. (NASDAQ: UNCY). It appears to be a financial data snippet from TradingView, indicating a specific financial ratio without providing extensive details or analysis. The content primarily list", "url": "https://www.tradingview.com/symbols/NASDAQ-UNCY/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T08:41:37", "published_display": "05 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Unicycive Therapeutics, Inc. \u2013 NASDAQ:UNCY", "summary": "The article discusses the forward price-to-earnings ratio for Unicycive Therapeutics, Inc. (NASDAQ: UNCY). It provides financial data and links to various tools and resources available on the TradingView platform for analyzing the stock.", "url": "https://www.tradingview.com/symbols/NASDAQ-UNCY/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T04:40:18", "published_display": "05 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY - Unicycive Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Unicycive Therapeutics Inc (UNCY) from Finviz. It includes a comprehensive overview of the company's financial data, stock performance metrics, insider ownership, institutional ownership, and analyst ratings. Key financi", "url": "https://finviz.com/stock?t=UNCY&b=2&p=d&ty=lf", "source_name": "Finviz", "published_at": "2026-07-04T21:41:34", "published_display": "04 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY - Unicycive Therapeutics Inc Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for Unicycive Therapeutics Inc (UNCY). It includes key financial metrics such as market capitalization, income, sales, EPS, and various ratios, alongside performance indicators like 52-week high/low, volatility, and", "url": "https://finviz.com/stock?t=UNCY&ta=1&p=d&ty=fc&b=2", "source_name": "Finviz", "published_at": "2026-07-04T20:41:38", "published_display": "04 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Unicycive Therapeutics (UNCY) Is Down 19.6% After FDA CRL Over Third-Party Manufacturing Issues And What's Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-04T17:34:01+00:00", "published_display": "04 Jul 2026 17:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY - Unicycive Therapeutics Inc Short Interest", "summary": "This article provides a detailed financial overview of Unicycive Therapeutics Inc (UNCY), focusing on its short interest. It covers key financial metrics, stock performance data, insider and institutional ownership, and various ratios, painting a comprehensive picture of the comp", "url": "https://finviz.com/stock?t=UNCY&b=2&p=d&ty=si", "source_name": "Finviz", "published_at": "2026-07-04T03:39:08", "published_display": "04 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the Firm", "summary": "Bragar Eagel & Squire, P.C. is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of its stockholders after the company announced a second Complete Response Letter from the FDA for its New Drug Application. This news led to a nearly 39% decline in Unicycive's sha", "url": "https://www.mycarrollcountynews.com/online_features/press_releases/article_15e47430-1e3d-5a52-bdd1-4616ad0a271d.html", "source_name": "Carroll County Mirror-Democrat", "published_at": "2026-07-02T17:40:45", "published_display": "02 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics reports $61.4M cash balance as of June 30, 2026", "summary": "Unicycive Therapeutics reported a preliminary cash balance of approximately $61.4 million as of June 30, 2026, indicating available liquidity. These stated results are preliminary, prepared by management, and have not been audited or reviewed by independent accountants. The compa", "url": "https://www.tradingview.com/news/tradingview:604c25e81556d:0-unicycive-therapeutics-reports-61-4m-cash-balance-as-of-june-30-2026/", "source_name": "TradingView", "published_at": "2026-07-02T14:40:44", "published_display": "02 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (UNCY) discloses $61.4M cash balance in preliminary Q2 2026 update", "summary": "Unicycive Therapeutics, Inc. reported a preliminary, unaudited cash balance of approximately $61.4 million as of June 30, 2026, as part of its second-quarter results. The company disclosed this information via an 8-K filing under Item 8.01, indicating a material event deemed impo", "url": "https://www.stocktitan.net/sec-filings/UNCY/8-k-unicycive-therapeutics-inc-reports-material-event-6447090bf357.html", "source_name": "Stock Titan", "published_at": "2026-07-02T14:40:44", "published_display": "02 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies", "summary": "Unicycive Therapeutics (UNCY) shares dropped 33.1% after the FDA issued a Complete Response Letter for its oxylanthanum carbonate NDA, citing third-party manufacturing deficiencies. The letter raised no concerns about clinical efficacy or safety, but instead highlighted unresolve", "url": "https://finance.yahoo.com/healthcare/articles/unicycive-therapeutics-uncy-down-33-221333290.html", "source_name": "Market source", "published_at": "2026-07-02T04:13:00", "published_display": "02 Jul 2026 04:13", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud", "summary": "Kirby McInerney LLP is investigating potential securities fraud claims against Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This investigation follows a significant 39% stock price drop after Unicycive announced a second Complete Response Letter from the FDA regarding its kidney ", "url": "https://www.businesswire.com/news/home/20260701488460/en/UNICYCIVE-THERAPEUTICS-INC.-INVESTOR-ALERT-Kirby-McInerney-LLP-Announces-Investigation-Into-Potential-Securities-Fraud", "source_name": "Business Wire", "published_at": "2026-07-01T22:39:18", "published_display": "01 Jul 2026 22:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Unicycive Therapeutics, Inc. SEC Filing", "summary": "This article reports on Unicycive Therapeutics, Inc.'s SEC Form 144 filing, which indicates a proposed sale of securities. The filing details the filer information, issuer information, securities to be sold including details of acquisition and payment, and confirms no securities ", "url": "https://www.stocktitan.net/sec-filings/UNCY/144-unicycive-therapeutics-inc-sec-filing-2a394680be50.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:39:18", "published_display": "01 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY ALERT: Unicycive Therapeutics, Inc. Investigated for", "summary": "Block & Leviton is investigating Unicycive Therapeutics, Inc. (UNCY) for potential securities law violations after the FDA issued a second Complete Response Letter for its OLC New Drug Application, citing unresolved third-party manufacturing deficiencies. This news led to a decli", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320812/23044/en/uncy-alert-unicycive-therapeutics-inc-investigated-for-securities-fraud-by-block-leviton-investors-who-lost-money-encouraged-to-contact-the-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T15:10:05", "published_display": "01 Jul 2026 15:10", "sentiment": "negative", "sentiment_pct": 25, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Unicycive Therapeutics Stock Falling Tuesday?", "summary": "Unicycive Therapeutics' stock fell over 46% after the FDA issued a Complete Response Letter (CRL) for its kidney disease drug application, citing third-party manufacturing deficiencies. This is the second time the FDA has raised these concerns, despite the company's belief that t", "url": "https://www.sahmcapital.com/news/content/why-is-unicycive-therapeutics-stock-falling-tuesday-2026-06-30", "source_name": "Sahm", "published_at": "2026-07-01T13:39:18", "published_display": "01 Jul 2026 13:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Inc", "summary": "Unicycive Therapeutics announced that the U.S. FDA has declined to approve its kidney disease drug for elevated phosphate levels in chronic kidney disease patients on dialysis. The FDA cited deficiencies at a third-party manufacturing facility as the reason for the non-approval.", "url": "https://www.reuters.com/company/unicycive-therapeutics-inc/", "source_name": "Reuters", "published_at": "2026-07-01T08:40:18", "published_display": "01 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Receives FDA Complete Response Letter for Oxylanthanum Carbonate NDA", "summary": "Unicycive Therapeutics announced it received a Complete Response Letter (CRL) from the FDA for its oxylanthanum carbonate (OLC) NDA, citing deficiencies at a third-party manufacturing vendor, not related to clinical efficacy or safety. The company is actively discussing labeling ", "url": "https://www.einpresswire.com/article/923415095/unicycive-therapeutics-receives-fda-complete-response-letter-for-oxylanthanum-carbonate-nda", "source_name": "EIN Presswire", "published_at": "2026-07-01T04:17:00", "published_display": "01 Jul 2026 04:17", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY Stock Clocks Worst Day In A Year \u2014 Analysts Keep Buy Ratings Despite \u20185-12 Month Delay\u2019 In Drug Approval", "summary": "Unicycive Therapeutics (UNCY) experienced its worst day in over a year after the FDA again refused to approve its drug oxylanthanum carbonate due to third-party manufacturing issues. Despite the setback and potential 5-12 month delay, B. Riley and H.C. Wainwright maintained their", "url": "https://stocktwits.com/news-articles/markets/equity/uncy-stock-clocks-worst-day-in-year-analysts-keep-buy-ratings-despite-5-12-month-delay-in-drug-approval/cZ1QMSoR70o", "source_name": "Stocktwits", "published_at": "2026-06-30T17:34:00", "published_display": "30 Jun 2026 17:34", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors", "summary": "Johnson Fistel, PLLP is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) following a decline in its stock price. This investigation comes after the FDA issued a second Complete Response Letter for Unicycive's OLC NDA due to unresolved third-party manufacturing deficienci", "url": "https://www.globenewswire.com/news-release/2026/06/30/3320031/0/en/johnson-fistel-investigates-unicycive-therapeutics-inc-nasdaq-uncy-on-behalf-of-investors.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T16:41:38", "published_display": "30 Jun 2026 16:41", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive gets FDA CRL for OLC kidney drug application", "summary": "Unicycive Therapeutics (NASDAQ:UNCY) received a Complete Response Letter (CRL) from the FDA for its oxylanthanum carbonate New Drug Application. The CRL cited third-party manufacturing deficiencies as the reason, with no issues raised regarding the drug's safety or efficacy. The ", "url": "https://grafa.com/en/news/united-states/unicycive-therapeutics-fda-crl-oxylanthanum-carbonate", "source_name": "grafa.com", "published_at": "2026-06-30T14:41:38", "published_display": "30 Jun 2026 14:41", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNCY Extends ATM Offering As Dilution Fears Hit The Chart", "summary": "Unicycive Therapeutics Inc. (NASDAQ: UNCY) shares have fallen by 46.04% due to investor concerns over clinical and financing uncertainties. The company filed a $150 million mixed securities shelf and expanded its at-the-market (ATM) equity program with Guggenheim Securities from ", "url": "https://stockstotrade.com/news/unicycive-therapeutics-inc-uncy-news-2026_06_30/", "source_name": "StocksToTrade", "published_at": "2026-06-30T13:41:38", "published_display": "30 Jun 2026 13:41", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA rejects drug again for same manufacturing issue, chopping stock in half", "summary": "The FDA has rejected Unicycive's kidney disease drug a second time, specifically citing an ongoing manufacturing issue with its Indian supplier. This decision caused the company's stock to drop by half. Despite the manufacturer supplying drugs for other U.S. companies, the FDA ha", "url": "https://www.bizjournals.com/sanfrancisco/news/2026/06/30/fda-unicycive-pdufa-dialysis-hyperphosphatemia.html", "source_name": "The Business Journals", "published_at": "2026-06-30T13:41:38", "published_display": "30 Jun 2026 13:41", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Gets FDA's Complete Response Letter for Resubmitted Oxylanthanum Carbonate NDA", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/unicycive-therapeutics-gets-fda-apos-122541738.html", "source_name": "MT Newswires", "published_at": "2026-06-30T12:25:41+00:00", "published_display": "30 Jun 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/unicycive-therapeutics-receives-complete-response-110500532.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T11:05:00+00:00", "published_display": "30 Jun 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Unicycive's kidney disease drug", "summary": "The U.S. FDA has declined to approve Unicycive Therapeutics' drug oxylanthanum carbonate (OLC) for chronic kidney disease patients due to deficiencies at a third-party manufacturing facility. This marks a second setback for the company, although the FDA had no concerns about the ", "url": "https://www.reuters.com/legal/litigation/us-fda-declines-approve-unicycives-drug-dialysis-patients-2026-06-30/", "source_name": "Reuters", "published_at": "2026-06-30T11:12:00", "published_display": "30 Jun 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNSEtlRDA2bmZmUnJubXJUMEJkeDJUUDlzWGg3ZEdjTmVva0hMcW5LcGhZSHZieF9wdTIwcHR5N1NheTFKYnpiZ2NTOFQ4SmNlZ2tfaVpWY1J6ZEVmODRNck56amRUSmFnZGhwLXgyZTRXWU1jQklvVnU0TlBieEJfcXF1Zmw1VW54V2ZfU2I4WTV0VHgwRlR2RHJwRQ?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Unicycive Therapeutics Stock Falling Tuesday? - Unicycive Therapeutics (NASDAQ:UNCY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPXzdRX1RURTVEbUh0V1RNa1Ayajk1TFcwbmo5bmlmQ2E0M1JjOXRNYXlLajRsRkR3UjFWZW1DRXJTVDJDdUdpU2g2d0wtWEs2V1FLVG02QXk2T1RPWTdJaDM0ZGlGQlBPT2JrYzdRMWpyNnZhMmZneVppVFhEM2RGTFB6WEtZRjFuakU5YTV1bFR1Wkw2Y2FmM3IyRVdKWUVKTVE?oc=5", "source_name": "Benzinga", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive\u2019s kidney drug hits FDA setback as label talks continue", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNSXVHd1RnSVJ4aTA0WEFPdkFXRDRKMHZBbGxJd0cwVDBPY3FiSDRxZjFWV2hYeUJfZDRhSkdWbjdiUVppeEZzcGxIcVVlSndBZllqRHEtRUo0eWRWZVM0SklqckRhc29DSWsxV0dyRlJGMFNvLWdpOENISnAwMk1DTEx0WDJGVW1WV3c4bW9rRW81alNfZHFwRFlYbzdLS2luUFkxV1NmaUNHVUo3RjRaYTBmZGVfNTRvMTk3TA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics stock tumbles on FDA rejection letter", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPRVMzZVI3allQaHR2T2hTRGhNc2ZqV1hsU3RBWGlDSVhEMnJmTE84QzZvWGNVZG9tbERVRFFMRUU4ZV9oQmN3Nm9lQWw2Uk1hTVljMWRuZnhNTHJEMFN3S1RYUnMwQjMxTjQ1QnZQckJpaXczNi1XLXZTMXp3UUtzU1lnNWRsWldVancyWE1FT2JWTl9RR3RjSzVjZ3doRDZnVUx4cWk2LXk4bE1HTXI5N2V4dVdNdlJVN1FTMGdfZw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive (UNCY) investors back board slate and 2026 auditor at meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQeGpheDBmNUQzNzF1amU5MWdpUllPN3RfaUlBX1BOUFlmUkZsVUI4LVdQREY1RlVjYzQ3UmZ6eHNTdDVCMjVKcjdod1RVX2pXdU8yUzZRcTl2QXdNNE5RbWQ3dHpFbGJfRnAyeDBOdThBQlNaeFl1U0M1UnNITDAtbW9mTVFRWWprZU9MdEc2RGh1N2paZlhPUFMxQTJzNHpjTHQ0VEdJTnNoRzdfSl93REVRVVZ4QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Stock - Wednesday strategy and pipeline snapshot", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxORjIyd3JqMWdjaHJydzFwVXhmcWFFVm1qd1JPY19LLXk0eHZldXB6QjI0cEhWX0pzX0wycV9kcUJKTjJ0clh1R1drcUJSWElxS2kzLVkySGtuVEtnVTJVemlrMktmUlRiM0xDN1RuT2hpVWFxV2VVU1dqZ2dEWUZXb2pvLWFrNHl1WHBKYUhLbnYyTGhPVUd0anBoanpEYVF5TUNaM25NQ09nUl9lQVFNNUQ5aGx6SFhILU5EWjNMdUMtRktoZWIw?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Unicycive Therapeutics, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPaXZydUh6eDlad0NlMVJpZEJ2SW5aXzh3cXFMbmUxVVRyUXBZRXB0UlllVTZlM09DNDJnM3E0c0NvTXdxZUZwT3ZKR0h5Q3FFWHlQZ2JJQW1HbGlOSDZTX2F2eHVzcTg3cmZuT2F5djVDSVRxeWVkcmExM1dkNVpnYUw1ZHNTaFBuLVRiTFRsSVNUa2UwUFg2WWN0dXM3Q1VHLU53OVd4QkZBQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (UNCY) CFO awarded 169,500 RSUs as stock compensation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQMHFkWFA2ZjE0T1E5RjhheDcwSWxydlJjSWRkSk95WndqVFk2UnJ0YUU4T3BrTDlNQzdjNHhVTVNBVlUxMGZuZWJwN2lDWVcxSVNhVi1vaEtKY3FmZl9KSUVYZ2toMkhGZjFqOHdzejY5b2RQSmhyUmlPVHFnZzhJSGFRTWJzcW1SUjl1cjJrbWc1Y3I0Y2ZmR19SM2pVQjZ3THFqUGx3WnFraG1ra3daM01sTWFQUF9lbExGT0MwWnNqTENCXzJYM0Zn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (UNCY) director receives sizeable new RSU awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQMGJKWkIxbWxmMGdWNk9lNGZNNF9aelZJemI4VjZwbnYyRXNkT0RwVEVsZFhYRG5wN2VaRHFYTExILVRmd3dpV1dISnFVaDlzY3ZtOHBCSU5QTVNqTXRtZkVIM05KY2RaMjVXM3Rpa3JmeXd0cmx1UW5fWjdycV9LUE1SaWhNUGhJUzhnNkc2Nmc1bXVfYlBweFItN2QtOHl5SzZabEdoWkVicGQ2bEo3STB6ZEpvRW96ck1LdXhCRHNfbWNrRFF4TkxR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyperphosphatemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 \u2013 DelveInsight | Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwJBVV95cUxQY1pPdElwWmZfMTEwUkpJUVhHRlhGWGxLMEVLaFZnUUE1SmlPNjJDNjdxWGcydEtoeEdrV09mYnBzMTg3R28wbU9YcmF3YlhXVFhHWXBhMU0zeTRCWGxGSWJUTndlZWJKb1JTcTJJZXJmVVFXaWkwVDktVHhzb2VMWE9WbDlrVHFZa1JOQWUxaVZlb044el95OGZ0eTZtTXpVaG5zZm5jdzZJZzhMZDBGMlFOS1VmSzRhRUk4SlNkLTU2dUVjWl9PaEVvVS1CNWpWUU01TzdkQm5HM3VoTU5YRUFIcG9YY0xSV3NmUVA5RS1zQ25HcGNyMkg3NmR3TFEwNXpNTnpMRGdhQUNCT1RxN2hUTTdMS3BLQWprNHVKeEdxM0lLdTF5a2xmMC1semdCU0pWaXl0aG4xaGpPbTY4WTMwbVd1Z3AxTXVGTkNFOA?oc=5", "source_name": "Barchart.com", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Raises ATM Offering of Shares", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/unicycive-therapeutics-raises-atm-offering-205833576.html", "source_name": "MT Newswires", "published_at": "2026-06-05T20:58:33+00:00", "published_display": "05 Jun 2026 20:58", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbjJHQS1tQVhGWkRqcGFOaW1VaTdXNFlvSV9hVlFfZXExVks0VkxmOTNmd1RONFhUR3o2VFplQnN6ZHBrZWdWM1lJSE1HaXZ5NGZySmVyNUEydmJGcGpzUFp4aFZCblhQdVJsWnJ5WXNpdFU5UmxISUpXQW9hV2w2cHdzbWUxZFNoMjlqdXF0ZE1wTW5vMFl1eThpNndfRU5jWDZ3VVVlWkNqd1Y1amtKQ1dDbC1pYU1I?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (UNCY) CEO receives 762,200 restricted stock units award", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNODhEQmd3dzl0dmk2MHd1cjRWRHF2aTMwY051aGNRUlpiYlk5ZU9zU3l0NDlwSmRMTG9Ba2N0WXJ0QUdNS2o4M1VCRHJZc19pMkdfeEZUUnlZTDdId3FIUW9uRU1UNENMeWNjU0ZKUVUyRDZuVVc0cHl3cXlxZEZ1cjAwWFJlelFacHB3NXpVU3daRnFvMGNEeWFWdXZ3VWt6S3BaUXpkNUtia3NzUW1CQ2hNQnc3S0htZlJ2dg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQN2dnLUNwTjc0T09WcElCQjBZb3U0UmdyRTd4dklsQU5FMVNJQUZVX09xOXV5MGVNMENPNWxXTE5EbU43TmpwUlJ5dW1Rd0hHV0hKT1A5OVVIaFM3ZXJvcU5tSG8tT1JNU0l3LUd4NTlrY0tmc2FiajNzWWNXYUVndW85RVBSX1hHemhGVUpCM3ZpQldkWkZkLWRITEpqYWtyeUIxZ0N1R2dEdw?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive Therapeutics Releases Q1 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQWVlkVjV3bUdGSWFsN0NVbDYzeVhJekdoZzdQMENMR3phX0NxbEtXa3FrQlpwU0trbmpPUFM4Y1UyQmUzQjR2ZTZOcC0wcUdoTEZqVlQtWGxKa1VZMHZtUjludzlEVjVJaHhSeTF6Zkc0UTBZbUNnZ1lqeFJjYlNtSWhnUlotOHFZbWlWeFhfaXrSAZABQVVfeXFMUFlZZFY1d21HRklhbDdDVWw2M3lYSXpHaGc3UDBDTEd6YV9DcWxLV2txa0JacFNLa25qT1BTOGNVMkJlM0I0dmU2TnAtMHFHaExGalZULVhsSmtVWTB2bVI5bnc5RFY1SWh4UnkxemZHNFEwWW1DZ2dZanhSY2JTbUloZ1JaLThxWW1pVnhYX2l6?oc=5", "source_name": "AlphaStreet", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive CEO gets April 15 speaking slot at Needham healthcare event", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZGJvSUNTM3RwZGd2cFVBZVpEUEM4aFF6NHloeTE3M0F4VmtqS2xaM3MxV3k4dzAzaU9xaW00RG5aRzVQTkZPRDVEM1Q0dkEwMTlWRHpBcmJRNmFjSkRZU1kxVW9IU2t5eUNfMk9oMkM0cHJMNFZqWUFuNU9qRFZMQjBUTHhhVDdmYkZqaUZmOGszSkptdnlTMFdlQTdOeS03QVRaUDhabk14VjY3Qk9iVm5XbmdrZlNJT0xoRlVBVzc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Unicycive Therapeutics (NASDAQ:UNCY) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unicycive readies kidney drug launch with FDA decision due June 29", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNSmIyR01ucGJObTZ3MkVSbk52SzZKLTZKYmE3XzJjbVJqSlNUUTNJU01IRTVkakVLMmRETy1ocXkwZnFLS3FmVjJUTDk0OHBMR21Nb3MzeGd3OFBfel8zbTdDRWVkYmdtRUM0QTBlX2dPUnZCeTU0QktzQlBjY29JcnNTRnk3aFRpYTB6czRqN19ob2ZqWHdBUmtkYjd3dmNyNU8wVVByVGFCaWMxaV9QUUZadlI1c0F5cjJpWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Might See A Profit From Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Soon", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 61, "sentiment_summary": {"positive": 10, "negative": 17, "neutral": 34, "score": 44, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 19.2, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.3, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 17}, "market_context": {"has_market_context": true, "latest_close": 5.21, "latest_week": "2026-07-10", "one_week_move": -9.1, "four_week_move": -28.1, "twelve_week_move": -25.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.677204, "market_dynamics_buy_signal": false, "relative_strength": -23.691221, "fair_value_gap": -24.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.2898, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.1% over one week, -28.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 8}, {"label": "GlobeNewswire", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "Finviz", "count": 3}, {"label": "The Globe and Mail", "count": 2}, {"label": "Stocktwits", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 17}, {"label": "Regulatory and legal", "count": 6}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "44/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.1% over one week, -28.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group"}], "updated_at": "2026-07-17T06:25:01.615749+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}